Viveve Medical (VIVE) Earns Buy Rating from Maxim Group

Maxim Group reissued their buy rating on shares of Viveve Medical (NASDAQ:VIVE) in a report published on Friday, March 16th. The brokerage currently has a $11.00 target price on the stock.

“4Q17 revenue of $5.1M, up 108% y/y, was inline with the preannouncement.”,” Maxim Group’s analyst commented.

How to Become a New Pot Stock Millionaire

Several other analysts also recently issued reports on VIVE. ValuEngine downgraded Viveve Medical from a sell rating to a strong sell rating in a research note on Thursday, March 1st. Mizuho restated a buy rating on shares of Viveve Medical in a report on Thursday, February 8th. Ladenburg Thalmann restated a buy rating on shares of Viveve Medical in a report on Thursday, January 4th. Finally, Northland Securities started coverage on Viveve Medical in a report on Friday, January 5th. They set an outperform rating and a $8.00 price target for the company. One investment analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $10.00.

Shares of VIVE traded down $0.10 during mid-day trading on Friday, reaching $3.19. The company had a trading volume of 221,663 shares, compared to its average volume of 301,358. The stock has a market cap of $102.76, a PE ratio of -1.51 and a beta of -0.49. Viveve Medical has a twelve month low of $3.12 and a twelve month high of $11.16. The company has a current ratio of 3.41, a quick ratio of 3.16 and a debt-to-equity ratio of -11.13.

Viveve Medical (NASDAQ:VIVE) last released its quarterly earnings results on Thursday, March 15th. The company reported ($0.53) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.47) by ($0.06). The business had revenue of $5.10 million for the quarter, compared to the consensus estimate of $5.09 million. Viveve Medical had a negative return on equity of 328.38% and a negative net margin of 241.75%. sell-side analysts forecast that Viveve Medical will post -1.44 EPS for the current fiscal year.

Large investors have recently modified their holdings of the company. Wells Fargo & Company MN raised its position in shares of Viveve Medical by 135.1% in the fourth quarter. Wells Fargo & Company MN now owns 37,727 shares of the company’s stock valued at $188,000 after buying an additional 21,683 shares in the last quarter. California State Teachers Retirement System acquired a new position in Viveve Medical during the second quarter valued at approximately $190,000. Teachers Advisors LLC acquired a new position in Viveve Medical during the second quarter valued at approximately $196,000. TIAA CREF Investment Management LLC acquired a new position in Viveve Medical during the second quarter valued at approximately $296,000. Finally, Neuberger Berman Group LLC bought a new stake in shares of Viveve Medical during the third quarter worth $419,000. Institutional investors own 40.19% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Viveve Medical (VIVE) Earns Buy Rating from Maxim Group” was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/07/viveve-medical-vive-rating-reiterated-by-maxim-group.html.

About Viveve Medical

Viveve Medical, Inc designs, develops, manufactures, and markets medical devices for the non-invasive treatment of various post-partum conditions. The company offers Viveve System, a radio frequency generator, a reusable hand piece, and single-use treatment tip, as well as other consumable accessories.

Analyst Recommendations for Viveve Medical (NASDAQ:VIVE)

Receive News & Ratings for Viveve Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viveve Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply